StreetInsider.com News Articles

Aclarion partners with Institute of Neuro Innovation for Nociscan expansion

Wed, 03 Jun 2026 06:00:50 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced an agreement with the Institute of Neuro Innovation, a Los Angeles-based neuroscience clinic, to expand availability of its Nociscan platform in the greater Los Angeles area.

The partnership will enable the multidisciplinary team led by neurosurgeon Amir Vokshoor to generate real-world evidence comparing Nociscan's chemical biomarker data with bone metabolic information from SPECT-CT imaging. The study aims to evaluate how the two diagnostic tools may work together for chronic low back pain treatment decisions.

"Chronic low back pain has become one of the most common issues we treat," said Vokshoor, founder of the Institute for Neuro

Aclarion partners with Institute of Neuro Innovation for Nociscan expansion

Wed, 03 Jun 2026 06:00:50 -0400

"Chronic low back pain has become one of the most common issues we treat," said Vokshoor, founder of the Institute for Neuro

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Wed, 03 Jun 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group
Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT
Supports scalable growth strategy while building data assets critical to payer and provider adoption

BROOMFIELD, Colo., June 03, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Wed, 03 Jun 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group
Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT
Supports scalable growth strategy while building data assets critical to payer and provider adoption

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Wed, 03 Jun 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group
Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT
Supports scalable growth strategy while building data assets critical to payer and provider adoption

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Wed, 03 Jun 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group
Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT
Supports scalable growth strategy while building data assets critical to payer and provider adoption

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Wed, 03 Jun 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group
Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT
Supports scalable growth strategy while building data assets critical to payer and provider adoption

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Wed, 03 Jun 2026 06:00:00 -0400

Expands availability of Nociscan in the greater Los Angeles area with leading neuroscience group
Adds to growing body of real-world evidence with study comparing chemical biomarker data from Nociscan with bone metabolic information from SPECT-CT
Supports scalable growth strategy while building data assets critical to payer and provider adoption

Aclarion technology used in back pain study exploring immune factors

Mon, 01 Jun 2026 06:00:34 -0400

Aclarion Inc. (NASDAQ: ACON, ACONW) announced that its Nociscan magnetic resonance spectroscopy technology was used in a research study examining biological factors associated with back pain in patients with Modic type 1 changes, a condition involving inflammation near spinal discs.

The study, conducted by investigators at University of Zurich, UCSF and the REACH Center, received the 2026 ISSLS Best Paper Award. Researchers used Nociscan's underlying MRS methodology to measure propionic acid, a metabolic byproduct associated with Cutibacterium acnes bacteria, inside lumbar discs.

The study found that elevated propionic acid levels identified a subgroup of Modic type 1 patients with distinct systemic immune

Aclarion technology used in back pain study exploring immune factors

Mon, 01 Jun 2026 06:00:34 -0400

The study found that elevated propionic acid levels identified a subgroup of Modic type 1 patients with distinct systemic immune

Aclarion technology used in back pain study exploring immune factors

Mon, 01 Jun 2026 06:00:34 -0400

The study found that elevated propionic acid levels identified a subgroup of Modic type 1 patients with distinct systemic immune

Aclarion technology used in back pain study exploring immune factors

Mon, 01 Jun 2026 06:00:34 -0400

The study found that elevated propionic acid levels identified a subgroup of Modic type 1 patients with distinct systemic immune

Aclarion technology used in back pain study exploring immune factors

Mon, 01 Jun 2026 06:00:34 -0400

The study found that elevated propionic acid levels identified a subgroup of Modic type 1 patients with distinct systemic immune

Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study